Multicenter, interventional, single-arm, phase IV study evaluating tolerability of Eribulin and its relationship with a set of polymorphisms in an unselected population of female patients with metastatic breast cancer
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 04 Jun 2019
Price : $35 *
At a glance
- Drugs Eribulin (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ESEMPiO; PAINTER
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 21 Aug 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 21 Aug 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.